SNDX Stock Up 27% after 6-Day Win Streak
Syndax Pharmaceuticals (SNDX) stock hit day 6 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 27% return. The company has gained about $369 Mil in value over the last 6 days, with its current market capitalization at about $1.4 Bil. The stock remains 20.0% above its value at the end of 2024. This compares with year-to-date returns of 9.6% for the S&P 500.
SNDX provides cancer therapies, focusing on SNDX-5613 in phase 1/2 trials targeting the Menin and mixed lineage leukemia 1 protein interaction. After this rally, is SNDX still a buy – or is it time to lock in gains? Deep dive with Buy or Sell SNDX.
Comparing SNDX Stock Returns With The S&P 500
The following table summarizes the return for SNDX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | SNDX | S&P 500 |
|---|---|---|
| 1D | 0.8% | -0.0% |
| 6D (Current Streak) | 27.2% | 0.9% |
| 1M (21D) | 67.8% | 2.4% |
| 3M (63D) | 75.4% | 8.2% |
| YTD 2025 | 20.0% | 9.6% |
| 2024 | -38.8% | 23.3% |
| 2023 | -15.1% | 24.2% |
| 2022 | 16.3% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has SNDX behaved after prior drops? See SNDX Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 20 S&P constituents with 3 days or more of consecutive gains and 103 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 6 | 95 |
| 4D | 3 | 6 |
| 5D | 8 | 1 |
| 6D | 1 | 0 |
| 7D or more | 2 | 1 |
| Total >=3 D | 20 | 103 |
Key Financials for Syndax Pharmaceuticals (SNDX)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $23.7 Mil |
| Operating Income | $-230.0 Mil | $-339.7 Mil |
| Net Income | $-209.4 Mil | $-318.8 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $20.0 Mil | $38.0 Mil |
| Operating Income | $-83.8 Mil | $-69.4 Mil |
| Net Income | $-84.8 Mil | $-71.8 Mil |
While SNDX stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.